Subscribe to our RSS feed

The Latest Health Stories

  • Is alcohol a gateway drug to chemsex?
  • Get your flu shots, poz people
  •  Measure for measure
  • Chasing the bug, chasing community
  • Falling

Starting Treatment Early

Sunday, 26 August 2012 Author // Guest Authors - Revolving Door Categories // As Prevention , Treatment Guidelines -including when to start, Research, Health, Treatment, Living with HIV, Revolving Door, Guest Authors

Three-quarters of clinicians in the US willing to prescribe early HIV treatment for the purpose of prevention, reports aidsmap

Starting Treatment Early

This article by Michael Carter first appeared on NAM/aidsmap Republished with permission. 

There is an overwhelming consensus among clinicians who prescribe HIV treatment in the US that people who are taking antiretroviral therapy are less likely to transmit HIV to their sexual partners, according to results of a study published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. Results also showed that over three-quarters of care providers would be willing to prescribe early therapy to people with an HIV-negative partner for the purposes of prevention.

The study involved 165 prescribing clinicians working at HIV clinics in the Bronx, New York, and Washington DC. It was conducted in 2010 and 2011, well before the publication of the results of the HPTN 052 study in the summer of 2012, which showed that virologically suppressive HIV treatment reduced the risk of transmission by 96%. US HIV treatment guidelines were updated in 2012 to endorse early treatment to reduce the risk of transmission.

“This survey of HIV clinicians in two US cities found most clinicians believe that ART [antiretroviral therapy] can reduce HIV transmission, even before the results of HPTN 052 demonstrated ART to be effective for this purpose, and before 2012 treatment guideline changes recommending ART for patients at risk for HIV transmission,” write the authors.

The research was conducted because the investigators wished to establish the beliefs of prescribing clinicians (doctors, nurse-practitioners and physician assistants) about the efficacy of antiretroviral therapy when used as prevention and their willingness to prescribe early treatment for individuals at risk of transmitting HIV to others.

Clinicians were recruited from centres participating in the HPTN 065 study, the main purpose of which is to evaluate the feasibility of community-expanded testing, linkage to care and treatment adherence as an HIV prevention strategy. The study does not involve early initiation of HIV therapy for prevention purposes.

Participants completed an internet-based survey. They had a median age of 46 years, 59% were women and two-thirds were white. The clinicians were highly experienced and had been caring for HIV-positive people for a median of 13 years. The overwhelming majority of their patients (85%) were already taking antiretroviral treatment and 6% of healthcare providers stated that all their patients were on therapy.

Overall, the clinicians showed an interest in the HIV risk behaviours of their patients. Three-quarters indicated that they regularly asked their patients about the HIV status of their sexual partners; 97% always or often enquired about condom use; and two-thirds stated that they enquired about injecting drug use. 

Almost all (95%) of the clinicians strongly agreed or agreed that “early initiation of ART can slow the spread of HIV in a community by making patients less infectious to others”.The participants were asked about their current prescribing practices. Most (92%) stated that they initiated treatment for the patient’s own health and based on the readiness of the individual to start therapy.

A small proportion of clinicians (15%) indicated that they recommended treatment at any CD4 cell count. The majority (56%) indicated that their current practice was to suggest treatment when a patient’s CD4 cell count fell below 500 cells/mm3.

A substantial majority (79%) of clinicians said that they would be more likely to recommend starting HIV therapy, irrespective of CD4 cell count, if a patient disclosed behaviour that involved a high risk of transmission. Three-quarters said they would be willing to offer early treatment if a patient had a partner who was HIV-negative.

However, a substantial proportion of clinicians had reservations about the early use of therapy. Just under half (47%) had concerns that this could lead to resistance and 52% were concerned about the risk of side-effects. A little under a third (30%) had concerns that early treatment could result in the transmission of drug-resistant virus to sex partners.

“There remains an inherent tension in prescribing ART to individuals for a population-benefit, when the risk-benefit profiles of multidecades-long treatment are not yet available,” comment the investigators. “Nonetheless there is emerging evidence that ART initiation at higher CD4 counts may have individual benefit.”

They conclude, “our findings suggest that clinicians will need to continue to balance information regarding efficacy of ART for prevention, with their duty to provide patients with interventions that have a favourable long-term benefit to their own health.”


Kurth AE et al. Clinical practices and attitudes regarding early antiretroviral therapy in the US. J Acquir Immune Defic Syndr, online edition. DOI: 10.1097/QAD0b013e31826a184c, 2012.

About the Author

Guest Authors - Revolving Door

Guest Authors - Revolving Door

The Revolving Door is the place where we publish occasional articles by guest writers. If you would like to submit an article for publication, please contact editor Bob Leahy at
  • Is alcohol a gateway drug to chemsex?

    Is alcohol a gateway drug to chemsex?

    From FS magazine: Intoxication plays a role in many of our early sexual experiences. How do those inform our understanding of sexual intimacy as we move into our late twenties and beyond? And will we indulge in chemsex?
  • Get your flu shots, poz people

    Get your flu shots, poz people

    Feel like a little prick? You should. Flu season is coming up and if you are HIV-positive, getting your flu shot soon is a no-brainer.
  •  Measure for measure

    Measure for measure

    How do we define success in both fighting HIV and in supporting people who live with it? How do we measure success and can those tools we have at our disposal provide the kind of accountability we should expect? Bob Leahy reports
  • Chasing the bug, chasing community

    Chasing the bug, chasing community

    Newly diagnosed Guest Author Joseph Sinnott says “I deliberately sought to be and was “pozzed", . Was I crazy? mad? insane? psychotic? Was my essential eroticization and subsequent pursuit of HIV deviant or perverted?
  • Falling

    Falling likes a brave and touching new video depicting how we in the LGBT community love, lose and support each other in the face of crystal meth addiction and recovery.
  • No to treating our way out of the epidemic, say South African experts

    No to treating our way out of the epidemic, say South African experts

    Consensus lacking on TasP? Some experts take a swing at treatment as prevention as a way to end the epidemic on a global scale
  • What hit hard at AIDS 2014

    What hit hard at AIDS 2014

    CATIE ED Laurie Edmiston “From the community perspective, AIDS 2014 was a strong conference, with an emphasis on key populations and the critical importance of human rights for these key populations.” And of course its emphasis on the treatment cascade
  • Security of PrEP

    Security of PrEP

    Poppy Morgan has been undecided whether or not to use PrEP to conceive her second child with her HIV-positive husband. What did she decide? Read on.
  • PrEP wars: The demonization of people using Truvada for prevention has backfired

    PrEP wars: The demonization of people using Truvada for prevention has backfired

    Poz AIDS activist Jim Pickett says hard-core PrEP opponents “distrust and mischaracterize science – either due to true misunderstanding or to cynical manipulation. They are stuck in a mind-set that posits condoms as the only valid form of HIV prevention."
  • PrEP pops up on cruising sites

    PrEP pops up on cruising sites

    Marc-André LeBlanc says that PrEP is a hot topic in HIV prevention circles. There is more and more discussion about it in gay media, on social networks, and even in mass media. But is it even on the radar of the average gay man?
  • PrEP works

    PrEP works reports high effectiveness seen in English PrEP trial; all participants in the PROUD study are to be offered PrEP early